SynthesisFrontiers in medicine2026
Diagnostic value of cystatin C in acute kidney injury among patients with sepsis: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study aimed to evaluate the diagnostic value of cystatin C (CysC) for the early detection of acute kidney injury (AKI) in patients with sepsis through a meta-analysis. Methods: Relevant studies were systematically retrieved from electronic databases using predefined search terms, including "sepsis," "acute kidney injury," and "diagnosis." Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. A random-effects meta-analysis was conducted using Stata 12.0 software to calculate pooled effect estimates and corresponding 95% confidence intervals (CIs). Subsequently, a summary receiver operating characteristic (SROC) curve was constructed, and the area under the curve (AUC) was calculated to evaluate overall diagnostic performance. Results: A total of 17 studies on cystatin C for diagnostic testing were included, and a random-effects model was applied for meta-analysis. The results indicated that cystatin C exhibited good diagnostic performance for sepsis-associated acute kidney injury (SA-AKI), with an AUC of 0.88, sensitivity of 0.81, and specificity of 0.82. Subgroup analyses further demonstrated that studies based on the Sepsis 3.0 criteria showed higher specificity and diagnostic odds ratio (DOR), along with reduced heterogeneity. In addition, the combination of cystatin C with other biomarkers further improved diagnostic accuracy. Overall, these findings suggest that cystatin C is a promising biomarker for the early diagnosis of SA-AKI. Conclusion: This meta-analysis demonstrates that cystatin C has considerable value for the early diagnosis of SA-AKI. Although heterogeneity among included studies remains, the overall evidence supports its potential applicability in clinical practice. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251128608, identifier PROSPERO (CRD420251128608).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.